source
- FDA grants three-month review extension for Exelixis' metastatic colorectal cancer candidateExelixis, a California drug developer, has provided the FDA with additional safety and efficacy data for its experimental therapy aimed at treating metastatic colorectal cancer. The agency respond…
- FDA signals openness to innovative trial designs for psychedelic therapiesFDA regulators said they are willing to consider more flexible approaches for evaluating psychedelic medicines. The agency noted that studies could use active comparators instead of placebo, which…